Acid Suppressants « Go Back
  • ULCITAB
  • ULCITAB - D
  • Qualitative & Quantitative Composition.

    Each enteric coated tablet contains Pantoprazole I.P. 40 mg.
  • Dosage Form

    Oral Tablets
  • Therapeutic indications

    Acid suppressant and Anti ulcerant
  • Dosage and administration

    1 tablet once daily
    As directed by physician
  • Contra-indications

    Patients sensitive to Pantoprazole or to any of the excipients of the product.
    Patients with severe heart failure, hypertension, hepatic or renal insufficiency.
  • Warnings and Precautions

    Long-term therapy may lead to bacterial overgrowth in the GI tract. Hepatic impairment; monitoring of liver functions regularly required (if enzymes increase, discontinue); pregnancy; not recommended in children < 18 yr; long term use may lead to atrophic gastritis. Must be used with caution in old age patients.
  • Drug interactions

    Decreased absorption of ketoconazole and itraconazole; may slightly increase digoxin plasma concentration; may reduce plasma concentration ofatazanavir, avoid concomitant use; may enhance anticoagulant effect of coumarins; may cause gastric mucosal irritation with alcohol; may increase levels or effects of: bosentan, dapsone, fluoxetine, glimepiride, glipizide, losartan, montelukast, nateglinide, paclitaxel, phenytoin, warfarin, and zafirlukast; may decrease levels or effects of: aminoglutethimide, carbamazepine, phenytoin, and rifampicin.
  • Pregnancy & lactation

    Category B.
  • Undesirable effects/side effects

    Diarrhoea, dizziness, pruritus, skin rashes, GI tract infections, chest pain, headache, nausea, pain, anxiety, hyperglycaemia; malaise or lassitude; myalgia; oedema; insomnia; hyperlipidaemia; flatulence, abdominal pain, constipation, eructation, dyspepsia, rectal disorder; urinary frequency, UTI; abnormalities in liver function; local site reaction; hypertonia, neck pain, weakness; bronchitis, cough, dyspnoea, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, flu syndrome.
  • Overdose

    Overdosage of Ulcitab should be avoided to overcome the serious adverse effects of pantoprazole.
  • Qualitative & Quantitative Composition.

    Each enteric coated tablet contains Pantoprazole I.P. 40 mg and Domperidone I.P. 10 mg.
  • Dosage Form

    Oral Tablets
  • Therapeutic indications

    Acid suppressant and Anti ulcerant
  • Dosage and administration

    1 tablet once daily
    As directed by physician
  • Contra-indications

    Patients hypersensitive to Pantoprazole and Domperidone or to any of the excipients of the product.
  • Warnings and Precautions

    Not recommended for children less than 12years.
    Patients with renal dysfunction or hepatic dysfunction.
  • Drug interactions

    The concomitant administration of anticholinergic drugs may compromise the beneficial effects of domperidone. Care should be exercised when domperidone is administered in combination with MAO inhibitors. No significant drug¬ interactions have been observed in clinical studies with pantoprazole.
  • Pregnancy & lactation

    Not recommended.
  • Undesirable effects/side effects

    Pantoprazole: Headache, Diarrhoea, Skin rash, Pruritus and Dizziness. Domperidone: Serum prolactin level may rise resulting in galactorrhea in females and less frequently gynaecomastia in males due to Domperidone. Dry mouth, Thirst, Headache, Nervousness,Drowsiness, Diarrhoea, Skin rashes and Itching may follow treatment with Domperidone.
  • Overdose

    Overdosage of Ulcitab-D should be avoided to overcome the serious adverse effects of Ulcitab – D.